Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, 2-stage study of INCB047986 administered orally to subjects with primary myelodysplastic syndrome (MDS) refractory to or unlikely to respond to erythropoiesis-stimulating agents (ESAs)

Trial Profile

A randomized, open-label, 2-stage study of INCB047986 administered orally to subjects with primary myelodysplastic syndrome (MDS) refractory to or unlikely to respond to erythropoiesis-stimulating agents (ESAs)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INCB 47986 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 22 Feb 2015 Status changed from active, no longer recruiting to discontinued due to business decision, as per ClinicalTrials.gov record.
    • 02 Sep 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
    • 03 Jun 2014 New source identified and integrated (Oregon Health and Science University).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top